

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Moore et al.

Application Serial No.: 09/263,626

Art Unit: 1646

#4

Filed: March 5, 1999

Examiner: O'Hara, E.

For: **Cytokine Receptor Common
Gamma Chain Like**

Attorney Docket No.: PF466

FEE TRANSMITTAL SHEET

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:



The fee required to be filed with the accompanying amendment of even date herewith concerning the above-identified application has been estimated to be \$984.00.

The claim amendment fee has been estimated as shown below:

(Col. 1)	(Col. 2)	(Col. 3)	SMALL ENTITY	OTHER THAN A SMALL ENTITY
Claims Remaining After Amendment	Highest No. Previously Paid For	Present Extra	Rate	Add. Fee
			or	Rate
				Add. Fee
Total	44	Minus	24	= 20
				X9
				\$ **
				X18
				\$ 360.00
Indep	11	Minus	3	= 8
				X39
				\$ **
				X78
				\$ 624.00
First Presentation of Multiple Dep. Claims			+ 135	\$ **
				+ 270
				\$ **
Total			\$ **	or
			Total	\$ <u>984.00</u>

Please charge the required fee, and any other fee deemed necessary, to Deposit Account No. 08-3425. A duplicate of this sheet is enclosed.

Respectfully submitted,

Dated: 10/18/99

Michele M. Wales
Michele M. Wales (Reg. No. 43,975)
Attorney for Applicants

Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, MD 20850
(301) 610-5772 (phone)

MMW/CB/ur

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Moore et al.

Application Serial No.: 09/263,626

Art Unit: 1646

Filed: March 5, 1999

Examiner: O'Hara, E.

For: **Cytokine Receptor Common
Gamma Chain Like**

Attorney Docket No.: PF466

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.56

Assistant Commissioner for Patents
Washington, D.C. 20231



S I R:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of an claim of the subject application, Attorneys for Applicants hereby direct the Examiner's attention to the references AA-AD listed on the attached form PTO 1449. A copy of references AA- is enclosed.

Applicants also wish to bring to the attention of the Examiner that SEQ ID NO:1 and the corresponding clone of the captioned application are related to: (1) SEQ ID NO:10291 in copending U.S. Patent application No. 08/798,074.


Identification of the listed references is not to be construed an admission of any individual associated with the filing or prosecution of the subject application that such references are available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.

Applicants respectfully request that the Examiner review the listed references and that the references be made of record in the file history of the application.

Pursuant to 37 C.F.R. § 1.97(b), since this information disclosure statement is being filed before the mailing date of a first Office Action on the merits, no fee is due in connection herewith. However, should the Patent Office determine otherwise, please charge the required fee to Human Genome Science, Inc., deposit account no. 08-3425. A copy of this sheet is enclosed.

Respectfully submitted,

Dated: 10/18/99


Michele M. Wales (Reg. No. 43,975)
Attorney for Applicants

Human Genome Sciences, Inc.

9410 Key West Avenue

Rockville, MD 20850

Telephone: (301) 610-5772

MMW/CB/ur

